After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for bladder cancer, making it the company’s first commercial-stage product. Anktiva (nogapendekin alfa ...
Johnson & Johnson has kicked off a marketing application in the US for TAR-200 as a treatment for a form of bladder cancer, using a novel technology that releases the drug intravesically, or directly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback